Nearly two weeks ahead of its presumed PDUFA date, sarecycline, branded Seysara, was greenlighted by the FDA to treat inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 9 and older. The once-daily, oral, narrow spectrum tetracycline-derived antibiotic was discovered by Paratek Pharmaceuticals Inc., which originally licensed U.S. development and commercialization rights to Warner Chilcott Ltd., which went to Actavis plc, now Allergan plc. In August, Almirall SA gained those rights in conjunction with its acquisition of Allergan's U.S. medical dermatology unit for $550 million in cash and a potential $100 million earn-out based on business performance. The transaction closed last week.